Share this
Celularity to Go Public Through SPAC Merger
Ovid - $75 Million IPO
VelosBio Agrees to Sell to Merck for $2.75 Billion
Genesis MedTech Acquires Drug Device Asset From TriReme Medical
Forbius Agrees to Sell to Bristol Myers Squibb
Neurocrine Partners With Takeda to Address Psychiatric Disorders
Orca Bio Raises $192 Million Series D to Transform Allogenic Cell Therapy
Avidity Biosciences - $289 Million IPO
Vaxcyte - $288 Milion IPO
Fate Therapeutics Licensing and Platform Collaboration with Janssen Biotech
Forty Seven Agrees to Sell to Gilead for $4.9 Billion
Reata Pharmaceuticals – $505 Million Follow-On Offering
argenx – $557 Million Follow-On Offering
Synthorx to Sell to Sanofi for $2.5 Billion
Avidity Biosciences – $100 Million Series C
Innate Pharma - $79 Million IPO
Vir Biotechnology - $143 Million IPO
Bavarian Nordic Acquires Two Commercial Vaccines from GlaxoSmithKline for €796 Million
Crown Bioscience Enters Merger Agreement With JSR Corporation
Sucampo Sells to Mallinckrodt for $1.2 Billion
Cell Design Labs Sells to Gilead
ERYTECH – $144 Million IPO
Cooley Advises on Nightstar + NuCana IPOs
Zealand Pharma – $89 Million IPO
Aridis – $26 Million IPO
Horizon Pharma Buys River Vision for $145 Million and Unspecified Earn-Out
SELLAS Life Sciences Group to Merge with Galena Biopharma
ZELTIQ Aesthetics to Sell to Allergan for $2.5 Billion
Medivation Agrees to Sell to Pfizer for $14 Billion
Advaxis – $30 Million Registered Direct Offering
Recro Pharma – $15 Million Follow-On
Gemphire Therapeutics – $30 Million IPO
Syros – $58 Million IPO
Syros IPO – $58 Million
Selecta Biosciences – $74 Million IPO
Jazz Pharmaceuticals Acquires Celator for $1.5 Billion
Oncobiologics – $40 Million IPO and Private Placement
Inotek Pharmaceuticals – $50 Million Follow-On
Syndax – $58 Million IPO
AveXis – $95 Million IPO
WAVE Life Sciences - $102 Million IPO
Voyager Therapeutics - $80.5 Million IPO
Cardioxyl Pharmaceuticals sale to Bristol-Myers Squibb
Strongbridge Biopharma IPO
Aclaris Therapeutics IPO
Bristol Meyers Enters Agreement with Five Prime
Medivation Expanding Oncology Franchise with Acquisition of Talazoparib from BioMarin
NantKwest IPO - $238 Million IPO
ProNAi Therapeutics - $158 Million IPO
Chiasma Completes $117 Million IPO
Celyad Completes IPO
NantKwest – $238 Million IPO
Catabasis Completes $69 Million IPO
ProNAi – $158 Million IPO
Axovant Completes $362 Million IPO
HTG Completes its Initial Public Offering
Jawbone Acquisition of Body Media
Aduro Completes $137 Million IPO
KemPharm Completes its IPO
Cidara Completes Initial Public Offering
Auspex Pharma $3.5 billion sale to Teva Pharma
Auspex Pharma Acquired by Teva for $3.5 Billion
Horizon Pharma Acquires Hyperion Therapeutics for $1.1 Billion
Invitae Completes $117 Million Initial Public Offering
Ascendis Pharma closes $124 million IPO
Bellicum Pharmaceuticals $160 million IPO
Nexvet Biopharma Closes Initial Public Offering
TRACON Pharmaceuticals Completes Initial Public Offering
Cooley Advises Xencor on its Initial Public Offering
NewLink Will License Ebola Vaccine to Merck
Ionis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes
Ionis Pharmaceuticals Completes Rule 144A Offering $500 Million of Convertible Senior Notes
Xenon Pharmaceuticals Completes Initial Public Offering
Atara – $63 Million IPO and Follow-On Offerings
DBV Technologies Completes Concurrent Public Offerings
Vascular Biogenics Prices IPO
Sientra Completes $75 Million Initial Public Offering
Demira Prices $125 Million IPO
T2 Biosystems IPO
NewLink Genetics Signs $1 Billion Deal with Genentech for Cancer Drug Research & Development
Vitae Pharmaceuticals Completes Initial Public Offering
Otonomy $100 Million IPO
Immune Design $63 Million Initial Public Offering
GlobeImmune Initial Public Offering
Intersect ENT Initial Public Offering
Minerva Neurosciences $32.7 Million IPO
Kite Pharma $146 Million Initial Public Offering
ProteinSimple $300 Million Sale to Techne Corporation
Alder Biopharmaceuticals $80 Million Initial Public Offering
Adamas Pharmaceuticals Initial Public Offering
TriVascular Initial Public Offering
Vital Therapies Initial Public Offering
Cooley Advises Underwriters on Vital Therapies IPO
Versartis $145 Million IPO
Horizon Pharma $660 Million Acquisition of Vidara Therapeutics
Amedica Initial Public Offering